Thermo Fisher Scientific (BOVESPA:TMOS34) - Aandelenkoers, Nieuws & Analyse

TMOS34 Overzicht aandelen

Thermo Fisher Scientific Inc. levert oplossingen voor de biowetenschappen, analytische instrumenten, diagnostische specialiteiten, laboratoriumproducten en biofarmaceutische diensten in Noord-Amerika, Europa, Azië-Pacific en internationaal.

Over het bedrijf

TMOS34 fundamentele analyse
Sneeuwvlok Score
Waardering	1/6
Toekomstige groei	1/6
Prestaties in het verleden	5/6
Financiële gezondheid	3/6
Dividenden	0/6

Beloningen

De winst zal naar verwachting met 10.55% per jaar groeien

De winst groeide het afgelopen jaar met 8.6%

Risicoanalyse

Heeft een hoog schuldenniveau

Thermo Fisher Scientific Inc. Concurrenten

Danaher

NYSE:DHR

US$198.2b

IQVIA Holdings

NYSE:IQV

US$43.1b

Lonza Group

SWX:LONN

CHF 39.9b

Agilent Technologies

NYSE:A

US$39.9b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Thermo Fisher Scientific
Historische aandelenkoersen
Huidige aandelenkoers	US$71.26
52 Week Hoogtepunt	US$75.93
52 Week Laag	US$43.97
Bèta	0.78
11 maand verandering	0.71%
3 maanden verandering	10.79%
1 Jaar Verandering	46.32%
33 jaar verandering	1.11%
5 jaar verandering	183.90%
Verandering sinds IPO	558.85%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	TMOS34	BR Life Sciences	BR Markt
7D	1.1%	0%	0%
1Y	46.3%	0%	0%

Rendement versus industrie: TMOS34 overtrof de BR Life Sciences industrie, die het afgelopen jaar een rendement 11.8 % opleverde.

Rendement versus markt: TMOS34 overtrof de BR markt, die het afgelopen jaar een rendement opleverde van 10.4 %.

Prijsvolatiliteit

Is TMOS34's price volatile compared to industry and market?
TMOS34 volatility
TMOS34 Average Weekly Movement	4.0%
Life Sciences Industry Average Movement	0%
Market Average Movement	0%
10% most volatile stocks in BR Market	0%
10% least volatile stocks in BR Market	0%

Stabiele aandelenkoers: TMOS34 heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 4% ) van TMOS34 is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1956	122,000	Marc Casper	www.thermofisher.com

Thermo Fisher Scientific Inc. levert life sciences oplossingen, analytische instrumenten, speciale diagnostica, laboratoriumproducten en biofarmaceutische diensten in Noord-Amerika, Europa, Azië-Pacific en internationaal. Het segment Life Sciences Solutions van het bedrijf biedt reagentia, instrumenten en verbruiksgoederen voor biologisch en medisch onderzoek, ontdekking en productie van medicijnen en vaccins, evenals diagnose van infecties en ziekten; en oplossingen voor biowetenschappen, genetische wetenschappen en bioproductie voor farmaceutische, biotechnologische, landbouw-, klinische, gezondheidszorg-, academische en overheidsmarkten. Het segment Analytische instrumenten levert instrumenten, verbruiksartikelen, software en diensten voor de farmaceutische, biotechnologische, academische, overheids-, milieu- en andere onderzoeks- en industriële markten, evenals klinische laboratoria.

Thermo Fisher Scientific Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Thermo Fisher Scientific zich tot de beurswaarde?
TMOS34 fundamentele statistieken
Marktkapitalisatie	R$1.30t
Inkomsten(TTM)	R$35.28b
Inkomsten(TTM)	R$240.21b

37.0x

Koers/Winstverhouding

5.4x

P/S-verhouding

Is TMOS34 overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
TMOS34 resultatenrekening (TTM)
Inkomsten	US$42.35b
Kosten van inkomsten	US$25.11b
Brutowinst	US$17.23b
Overige uitgaven	US$11.01b
Inkomsten	US$6.22b

Laatst gerapporteerde inkomsten

Jun 29, 2024

Volgende inkomensdatum

Oct 23, 2024

Winst per aandeel (EPS)	16.28
Brutomarge	40.69%
Nettowinstmarge	14.69%
Schuld/Eigen Vermogen Verhouding	74.1%

Hoe presteerde TMOS34 op de lange termijn?

Bekijk historische prestaties en vergelijking

Dividenden

0.3%

Huidig dividendrendement

9%

Uitbetalingsratio

Betaalt TMOS34 een betrouwbaar dividend?

Zie TMOS34 dividendgeschiedenis en benchmarks

Wanneer moet je TMOS34 kopen om een aanstaand dividend te ontvangen?
Thermo Fisher Scientific dividenddata
Ex Dividend Datum	Sep 12 2024
Betaaldatum dividend	Oct 21 2024
Dagen tot Ex-dividend	40 days
Dagen tot dividendbetaaldatum	1 day

Betaalt TMOS34 een betrouwbaar dividend?

Zie TMOS34 dividendgeschiedenis en benchmarks

TMOS34 Overzicht aandelen

Beloningen

Risicoanalyse

Thermo Fisher Scientific Inc. Concurrenten

NYSE:DHR

US$198.2b

NYSE:IQV

US$43.1b

SWX:LONN

CHF 39.9b

NYSE:A

US$39.9b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Thermo Fisher Scientific Introduces Fully Integrated Multimodal Analytical Scanning Transmission Electron Microscope to Advance Novel Research in Materials Science

Thermo Fisher Scientific Introduces Mass Spectrometers to Simplify Trace Elemental Analysis and Enhance Productivity

Thermo Fisher Scientific Inc. to Report Q3, 2024 Results on Oct 23, 2024

FDA Grants Thermo Fisher Scientific Inc.'s SeCore HLA Typing Kit 510(k) Clearance for Use as Companion Diagnostic with a T-Cell Receptor Therapy for Synovial Sarcoma

Thermo Fisher Scientific Inc. Announces Extended 510k Clearance of Freelite Assays for Evaluation of MGUS

Thermo Fisher Scientific Inc. Showcases Diagnostics Innovation Across Therapeutic Areas at ADLM 2024

Recent updates

Thermo Fisher Scientific Introduces Fully Integrated Multimodal Analytical Scanning Transmission Electron Microscope to Advance Novel Research in Materials Science

Thermo Fisher Scientific Introduces Mass Spectrometers to Simplify Trace Elemental Analysis and Enhance Productivity

Thermo Fisher Scientific Inc. to Report Q3, 2024 Results on Oct 23, 2024

FDA Grants Thermo Fisher Scientific Inc.'s SeCore HLA Typing Kit 510(k) Clearance for Use as Companion Diagnostic with a T-Cell Receptor Therapy for Synovial Sarcoma

Thermo Fisher Scientific Inc. Announces Extended 510k Clearance of Freelite Assays for Evaluation of MGUS

Thermo Fisher Scientific Inc. Showcases Diagnostics Innovation Across Therapeutic Areas at ADLM 2024

Thermo Fisher Scientific Inc. Raises Earnings Guidance for the Year 2024

Thermo Fisher Scientific to Help Advance Myeloid Cancer Clinical Research and Treatment Utilizing Next Generation Sequencing Technology

Thermo Fisher Scientific Inc. (NYSE:TMO) completed the acquisition of Olink Holding AB (publ) (NasdaqGM:OLK) from Summa Equity AB and others.

Thermo Fisher Scientific Inc. to Report Q2, 2024 Results on Jul 24, 2024

Thermo Fisher Scientific Inc.(NYSE:TMO) dropped from Russell 1000 Growth-Defensive Index

Thermo Fisher Scientific Introduces the Only Fully Automated Plasmid Purification System to Help Accelerate Discovery and Development of Therapies

Thermo Fisher Scientific Introduces Thermo Scientific Heracell VIOS 250i AxD CO2 Incubators

Thermo Fisher Scientific Introduces Innovative Mass Spectrometer to Advance Clinical Research

Thermo Fisher Scientific Updates Chromosomal Microarray Analysis Solutions to Comply with IVDR Regulation

Thermo Fisher Scientific Inc. Declares Quarterly Dividend, Payable on July 15, 2024

Thermo Fisher Scientific Introduces Array-Based Solution for Extended Blood Type Research to Support Future Advancements Toward Safer Transfusions

Thermo Fisher Scientific Inc. Raises Revenue Guidance for the Full Year 2024

Thermo Fisher Scientific Inc. Introduces Animal Origin-Free Formulation to Support Scaling of Cell Therapy Manufacturing

Thermo Fisher Scientific Inc., Annual General Meeting, May 22, 2024

Thermo Fisher Scientific Introduces Its Newest Line of High Performance, Ultra-Low Temperature (ULT) Freezers

Thermo Fisher Scientific Inc. to Report Q1, 2024 Results on Apr 24, 2024

Thermo Fisher Scientific Announces A New In-Line Metrology Solution to Improve Battery Safety and Performance

Thermo Fisher Scientific Inc. Launches Corevitas Clinical Registry in Generalized Pustular Psoriasis

Thermo Fisher Scientific Inc. Increases Quarterly Cash Dividend, Payable on April 15, 2024

Thermo Fisher Scientific Inc. Launches New Ion Chromatography Instrument to Improve Reliability, Efficiency, and Functional Adaptability for Labs

Thermo Fisher Scientific Expands GMP Laboratory Service Offerings with Biosafety Testing Including Mycoplasma Testing

Thermo Fisher Scientific Inc. Announces Earnings Guidance for Full Year 2024

Thermo Fisher Scientific Appoints Srinath Venkatesh as Managing Director, India and South Asia

Thermo Fisher Scientific Receives GMP Approval from the Italian Medicines Agency for its Manufacturing Facility of RNA-Based Products in Monza, Italy

Thermo Fisher Scientific Inc. Announces Launch of Innovative Corevitas Pharmacovigilance Platform for Clinical Research Registries

Thermo Fisher Scientific Inc. Announces the Launch of the Thermo Scientific KingFisher Apex Dx and Applied Biosystems MagMAX Dx Viral/Pathogen NA Isolation Kit

Thermo Fisher Scientific Declares Quarterly Dividend, Payable on January 16, 202

Thermo Fisher Scientific Announces New Fault Localization Solution for the Analysis of Advanced Logic Semiconductors

Thermo Fisher Scientific Inc. Provides Earnings Guidance for the Year 2023

Thermo Fisher Scientific Inc. (NYSE:TMO) proposed an offer to acquire Olink Holding AB (publ) (NasdaqGM:OLK) from Summa Equity AB and others for approximately $3.3 billion.

Thermo Fisher Scientific Inc. (NYSE:TMO) proposed an offer to acquire Olink Holding AB (publ) (NasdaqGM:OLK) from Summa Equity AB and others for approximately $3.3 billion.

Thermo Fisher Scientific Inc. to Report Q3, 2023 Results on Oct 25, 2023

Thermo Fisher Scientific Inc. Appoints Jennifer “Jenny” Johnson to the Audit Committee

Thermo Fisher Scientific Helps Accelerate Cell Therapy Manufacturing with A Next-Generation Platform of Gibco™ CTS™ Detachable Dynabeads™

Thermo Fisher Scientific Announces the Launch of the EXENT Solution with IVDR Certification

Thermo Fisher Scientific Introduces New Chromosomal Microarray with Two-Day Turnaround Time to Increase Lab Productivity

Thermo Fisher Scientific Inc. (NYSE:TMO) acquired CorEvitas, LLC from Audax Management Company, LLC for approximately $910 million.

Thermo Fisher Scientific Announces a New Line of Thermo Scientific TM TSG Series Refrigerators

Thermo Fisher Scientific Inc. Revises earnings Guidance for 2023

Thermo Fisher Scientific Introduces New Reproductive Health Assays to Accelerate Fertility Research

Thermo Fisher Scientific Inc. Elects Jenny Johnson to Board of Directors

Thermo Fisher Scientific Inc. (NYSE:TMO) has entered into a definitive agreement to acquire CorEvitas, LLC from Audax Management Company, LLC for Approximately $910 million.

Thermo Fisher May Be Leading Bidder to Buy CorEvitas

Thermo Fisher Scientific Announces Launch of Gibco™ OncoPro™ Tumoroid Culture Medium Kit

Thermo Fisher Scientific Inc. (NYSE:TMO) completed the acquisition MarqMetrix, Inc.

Thermo Fisher Scientific Introduces Groundbreaking Mass Spectrometer to Revolutionize Biological Discovery

Thermo Fisher Scientific Inc. Declares Quarterly Cash Dividend, Payable on July 14, 2023

Montrose Environmental Group, Inc. Announces Global Collaboration with Thermo Fisher Scientific Inc. to Provide A Comprehensive Real-Time Ethylene Oxide Monitoring Solution Meets Recent Release U.S. Environmental Protection Agency Regulations

Thermo Fisher Scientific Inc., Annual General Meeting, May 24, 2023

Warburg, Advent Reportedly in Lead to Acquire Baxter's Biopharma Unit

Thermo Fisher Scientific Launches TrueMark STI Select Panel

Thermo Fisher Scientific Inc. Provides Earnings Guidance for the Full Year 2023

Thermo Fisher Scientific Inc. Launches CE-IVD Marked Assay to Detect Treatment-Resistant Strains of HIV-1